# A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct03742102/  
OnCo record `nct03742102` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Durvalumab, Capivasertib, Oleclumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT03742102 by AstraZeneca, with 243 participants enrolled, started 2018-12-21 and due to reach its primary completion in 2024-11-29. Interventions recorded: Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan and Datopotamab deruxtecan. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03742102
- Phase: 1/2
- Setting: A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer
- Sponsor: AstraZeneca
- Enrolled: 243

## Sources

- ClinicalTrials.gov NCT03742102: https://clinicaltrials.gov/study/NCT03742102

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Capivasertib](https://onco.cc/drugs/capivasertib/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Oleclumab](https://onco.cc/drugs/oleclumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct03742102.json